The TRPM6/EGF Pathway Is Downregulated in a Rat Model of Cisplatin Nephrotoxicity

Ledeganck, Kristien J.; Boulet, Gaëlle A.; Bogers, Johannes J.; Verpooten, Gert A.; De Winter, Benedicte Y.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Cisplatin-induced hypomagnesemia is described in humans and rats, but the underlying mechanisms are still unclear. Recent studies have shown that epidermal growth factor (EGF) stimulates Mg2+ re-absorption in the distal convoluted tubule via the Mg2+ channel TRPM6. This study investigates the role of TRPM Mg2+ channels, claudines, and EGF in the Mg2+ homeostasis in a rat model of cisplatin-induced nephrotoxicity. Wistar rats were given 2.5 mg/kg cisplatin per week for 3 weeks and were euthanized 4 or 9 weeks after the first administration. The cisplatin treatment significantly increased the fractional excretion of Mg2+. Real-time RT-PCR and/or Western blots were performed to assess the renal expression TRPM6, TRPM7, claudin-16, claudin-19, EGF, EGF receptor (EGFR) and EGFR-pathway components. The renal mRNA expression of TRPM6 and EGF showed a significant decrease after cisplatin treatment, while the TRPM7, claudin-16 and EGFR expressions remained stable. The claudin-19 mRNA expression was significantly upregulated after cisplatin treatment. Western blotting confirmed the mRNA expression data for the claudins, but an showed upregulation of EGFR only at week 9. The role of the EGFR pathway, involving Pi3-AKT-Rac1, in cisplatin-induced nephropathy, could not be substantiated in further detail. This study shows that cisplatin treatment results in EGF and TRPM6 downregulation in the rat kidney, causing renal Mg2+ loss. Our results are in line with the hypothesis that EGF influences the renal expression or activation of TRPM6 and plays a significant role in Mg2+ loss in medication-induced nephropathy.


Related Articles

  • Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats. Wada, Yukihiro; Iyoda, Masayuki; Matsumoto, Kei; Shindo-Hirai, Yuki; Kuno, Yoshihiro; Yamamoto, Yasutaka; Suzuki, Taihei; Saito, Tomohiro; Iseri, Ken; Shibata, Takanori // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    The effects of blocking the epidermal growth factor receptor (EGFR) in acute kidney injury (AKI) are controversial. Here we investigated the renoprotective effect of erlotinib, a selective tyrosine kinase inhibitor that can block EGFR activity, on cisplatin (CP)-induced AKI. Groups of animals...

  • Inhibiting EGFR Dimerization Using Triazolyl-Bridged Dimerization Arm Mimics. Hanold, Laura E.; Oruganty, Krishnadev; Ton, Norman T.; Beedle, Aaron M.; Kannan, Natarajan; Kennedy, Eileen J. // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    The epidermal growth factor receptor (EGFR) is overexpressed in multiple carcinomas and is the focus of a variety of targeted therapies. Here we report the design of peptide-based compounds that mimic the EGFR dimerization arm and inhibit allosteric activation of EGFR. These peptides are...

  • Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Gong, Jian-hua; Liu, Xiu-jun; Li, Yi; Zhen, Yong-su // Cancer Chemotherapy & Pharmacology;May2012, Vol. 69 Issue 5, p1323 

    Purpose: As reported, epidermal growth factor receptor (EGFR) is over expressed in a variety of cancers including esophageal squamous cell carcinoma. Therefore, it becomes one of the potential targets for treating esophageal cancer. Pingyangmycin (PYM), a single A5 component of bleomycin, is...

  • Identification of Platform-Independent Gene Expression Markers of Cisplatin Nephrotoxicity. Thompson, Karol L.; Afshari, Cynthia A.; Amin, Rupesh P.; Bertram, Timothy A.; Car, Bruce; Cunningham, Michael; Kind, Clive; Kramer, Jeffrey A.; Lawton, Michael; Mirsky, Michael; Naciff, Jorge M.; Oreffo, Victor; Pine, P. Scott; Sistare, Frank D. // Environmental Health Perspectives;Mar2004, Vol. 112 Issue 4, p488 

    Within the International Life Sciences Institute Committee on Genomics, a working group was formed to focus on the application of microarray technology to preclinical assessments of drug-induced nephrotoxicity. As part of this effort, Sprague-Dawley rats were treated with the nephrotoxicant...

  • Lipid Peroxidative Damage on Cisplatin Exposure and Alterations in Antioxidant Defense System in Rat Kidneys: A Possible Protective Effect of Selenium. Ognjanović, Branka I.; Djordjević, Nataša Z.; Matić, Miloš M.; Obradović, Jasmina M.; Mladenović, Jelena M.; Štajn, Andraš Š.; Saičić, Zorica S. // International Journal of Molecular Sciences;Feb2012, Vol. 13 Issue 2, p1790 

    Cisplatin (Cis-diamminedichloroplatinum II, CP) is an important chemotherapeutic agent, useful in the treatment of several cancers, but with several side effects such as nephrotoxicity. The present study investigated the possible protective effect of selenium (Se) against CP-induced oxidative...

  • 2,2′-Diphenyl-3,3′-Diindolylmethane: A Potent Compound Induces Apoptosis in Breast Cancer Cells by Inhibiting EGFR Pathway. Bhowmik, Arijit; Das, Nilanjana; Pal, Uttam; Mandal, Madhumita; Bhattacharya, Seemana; Sarkar, Moumita; Jaisankar, Parasuraman; Maiti, Nakul C.; Ghosh, Mrinal K. // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Despite recent advances in medicine, 30–40% of patients with breast cancer show recurrence underscoring the need for improved effective therapy. In this study, by in vitro screening we have selected a novel synthetic indole derivative 2,2'-diphenyl-3,3'-diindolylmethane (DPDIM) as a...

  • Paired-box gene 2 is down-regulated in endometriosis and correlates with low epidermal growth factor receptor expression. de Graaff, A.A.; Delvoux, B.; Van de Vijver, K.K.; Kyama, C.M.; D'Hooghe, T.M.; Dunselman, G.A.J.; Romano, A. // Human Reproduction;Jun2012, Vol. 27 Issue 6, p1676 

    BACKGROUND Paired-box 2 (Pax2) is involved in the development of the female genital tract and has been associated with endometrial pathologies. The expression of Pax2 is induced by epidermal growth factor (EGF) and estrogens. In the present study, Pax2 expression and regulation were investigated...

  • Pertuzumab: new hope for patients with HER2-positive breast cancer. Capelan, M.; Pugliano, L.; De Azambuja, E.; Bozovic, I.; Saini, K. S.; Sotiriou, C.; Loi, S.; Piccart-Gebhart, M. J. // Annals of Oncology;Feb2013, Vol. 24 Issue 2, p273 

    Background Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurred since trastuzumab therapy was introduced into daily clinical practice....

  • Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Brain, E; Isambert, N; Dalenc, F; Diéras, V; Bonneterre, J; Rezai, K; Jimenez, M; Mefti-Lacheraf, F; Cottura, E; Tresca, P; Vanlemmens, L; Mahier-Aït Oukhatar, C; Lokiec, F; Fumoleau, P // British Journal of Cancer;2/14/2012, Vol. 106 Issue 4, p673 

    Background:To determine the recommended doses of lapatinib (LPT) combined with vinorelbine (VNR) in women with human epidermal growth factor receptor 2-overexpressing advanced breast cancer pretreated with trastuzumab.Methods:In this phase I study, women were treated with oral daily LPT and i.v....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics